CATAG Newsletter May 2012

Posted on May 31, 2012



File size: 0.10MB


Posted in CATAG Newsletters

MAP Jurisdiction Template

Posted on April 30, 2012



File size: 0.01MB

Posted in CATAG Documents

Guiding Principles for Medicines Access Programs in Australian Public Hospitals

Posted on April 30, 2012



File size: 0.10MB

Posted in CATAG Documents

Member Activities

Posted on June 6, 2011

  • NSW TAG is advertising for a new executive officer. Job advertisment attached.
  • QHMAC Annual Report 2009 has been released.
  • The heparin chart is attached.

Download: VICHeparin-chartfinal_1005204

Posted in CATAG

Conference Attendance

Posted on June 6, 2010

NHMRC/NICS/ACSQHC VTE Prevention Policy Summit, 17 May 2010

Delegates included representatives from each jurisdiction, TGA, private hospitals, VTE Prevention Guideline Committee,the National Prescribing Service, the Clinical Excellence Commission in NSW, and CATAG. It was good to catch up with Amber and PK who both attended the summit. Attached is a draft summary guideline and consumer pamphlet provided for comment on the day. If you have any comments on these documents please email Agnes Wilson directly by 10th June

UNSW New and Emerging Cancer Therapies: From Hype to Reality, 26 May 2010

Dr Euan Walpole from QHMAC and myself represented CATAG at this symposium. Discussed on the day were current problems with funding targetted cancer therapies including issues around testing required to determine eligibility for treatment. Three different models of funding/health care provision were discussed. This discussion was useful for informing further work around funding other high-cost medicines.

NPS National Medicines Symposium 26-28 May 2010

For those CATAG colleagues who also attended NMS it was great to catch up with you. The symposium presented an excellent opportunity for networking and promoting the role of CATAG to the wider QUM community.

Posted in CATAG

CATAG Activities

Posted on June 6, 2010

NMP Partnerships Forum Submission

As you will recall this was submitted in early May. I have now heard back from Andrew McLachlan that all the issues we raised were endorsed by the NMP committee and referred to the NMP executive. Andrew McLachlan also mentioned it was greatly appreciated that we had provided potential solutions alongside the issues we raised. Paul Seale will be attending the NMP partnerships Forum on behalf of CATAG on the 30th June.

Oxycodone Patch

The letter re mindful naming of a future oxycodone patch has been sent to Phosphagenics.


Letters advising Medicines Australia, SHPA and NPS of our renewal of our position on samples has been sent.

Generic medicines issues

I have discussed CATAG concerns re labelling/packaging of generic medicines and standardisation of CMI with Andrew McLachlan in his capacity as Chair of the NMP Committee. He advised writing to the following individuals/organisations: Dr Rohan Hammett (TGA), Therapeutic Goods Committee, Medicines Partnership of Australia, Medicines Australia and Generic Medicines Industry Association. To strengthen our case he also suggesting we collect anecdotal data of safety issues from public hospitals to highlight the risk of dose and drug duplication especially around the labelling/packaging issues. Please notify me of any anecdotes you are aware of regarding these issues and I will incorporate it into our communication.

Posted in CATAG

CATAG Vision, Strategic Direction, Governance and Organisational Relations

Posted on June 6, 2010

Terms of Reference

Thank you to all who commented on our Mission, Goals, Objectives and Strategies. These have now been finalised and are attached. Please circulate theses to your membership and they may be posted on your websites. Please note issues around CATAG governance and structure have been deleted from this document as they have not been finalised pending decisions around becoming an incorporated body.

Legal Advice

I have received legal advice regarding the issues around incorporation of CATAG

either as an incorporated association in NSW or as a public company limited by

guarantee. The advice also covers managing potential conflicts of interest that

may arise. I am preparing an options paper to accompany this advice and will

circulate all relevant information via a separate communication in the coming


Posted in CATAG